SMYD2 promotes cervical cancer growth by stimulating cell proliferation

Abstract

Background Cervical cancer is the most common gynecological malignancy with low terminal cure rate, and therefore new therapeutic targets are urgently needed to combat this disease. SMYD2, as an oncogene, is abnormal highly expressed in multiple types of tumors and further affects the occurrence and development, but the potential correlations between SMYD2 expression and cervical cancer progression is still unclear. Methods We first used the bioinformatics website to screen the data of cervical cancer in (The Cancer Genome Atlas) TCGA and survival analysis was used to find the different survival rates in the SMYD2 high expression group and low expression group. Through immunohistochemistry, the association between SMYD2 expression and clinical-pathological features of cervical cancer patients was further evaluated. Quantitative PCR and Immunoblot were applied to investigate the relative mRNA and protein expression levels, respectively. In vivo and in vitro experiments were performed to explore the function of SMYD2 in cancer progression. Results We first found a high expression of SMYD2 in cervical cancer, and survival analysis found that the poorer survival rate in the SMYD2 high expression group than that in the low expression group. Herein, our study demonstrated that the expression of SMYD2 in patients with cervical cancer was associated with FIGO stage, tumor size and further correlated with poor prognosis. Our data further showed that the inhibition of SMYD2 expression in cervical cancer cell line Caski and Siha could dramatically block the proliferation of cervical cancer cells. Additionally, SMYD2-shRNA lentivirus infected remarkably inhibited tumorigenesis in mice compared with the scramble group. Conclusions Taken together, this study provides strong evidence of the involvement of SMYD2 in cervical cancer growth and indicates that it could have high potential as a therapeutic target of cervical cancer.

Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry

“…SETD3-positivity has been reported to be associated with poor prognosis in hepatocellular carcinoma (32). Similar to our expression profile, high levels of SMYD2 expression has been associated with unfavorable prognosis in different cancer types, such as breast cancer (mRNA expression) and cervical cancer (protein expression) (33,34). A recent study reported overexpression of SMYD2 in cancer vs. normal tissue, and associated higher expression of SMYD2 with enhanced proliferation in HGSC (35).…”

The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells

“…For example, SMYD2 is upregulated in gastric cancer and has important effects on cell proliferation (26). In the field of gynecologic cancer, an association between poor prognosis of cervical cancer and SMYD2 upregulation has been reported (29). Additionally, our previous study indicated that SMYD2 knockdown could suppress HGSOC cell proliferation and induce apoptosis (18).…”

Identification of Potential Biomarkers for Progression and Prognosis of Bladder Cancer by Comprehensive Bioinformatics Analysis

“…Mechanically, SMYD2 may promote carcinogenesis and metastasis by activating RPS7 transcription through binding to its promoter [ 24 ]. Inhibition of SMYD2 expression has been shown to significantly reduce cervical cancer proliferation in vivo and in vitro [ 25 ]. Furthermore, Meng et al found that SMYD2 inhibits the expression of APC2, thereby activating the Wnt/ β -catenin signaling pathway and promoting the epithelial-mesenchymal transition in colorectal cancer [ 26 ].…”